SCHEMBL1363718

SCHEMBL1363718

Cc1c(N[C@@H](C(=O)NNC(=O)c2ccc(Cl)cc2)[C@H](C)O)ccc(C#N)c1Cl

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 3/20 0.43
PGR P06401 2/20 0.42
S1PR3 Q99500 6/20 0.40
POLB P06746 2/20 0.40
SMN1; SMN2 Q16637 3/20 0.38
MAPT P10636 2/20 0.38
HTT P42858 2/20 0.38
LMNA P02545 1/20 0.38
GALK1 P51570 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
S1PR1 P21453 2/20 0.37
NR3C1 P04150 1/20 0.37
KDM4E B2RXH2 1/20 0.37
TLR7 Q9NYK1 1/20 0.37
ALDH1A1 P00352 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C9 P11712 1/20 0.36
ALOX12 P18054 1/20 0.36
CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1363222 1.00 AR (0.43) ARPGRS1PR3POLBSMN1; SMN2
SCHEMBL12307978 0.94 AR (0.43) ARPGRS1PR3SMN1; SMN2MAPT
SCHEMBL1363767 0.94 AR (0.43) ARPGRS1PR3NR3C1
SCHEMBL1364665 0.94 AR (0.43) ARPGRS1PR3NR3C1
SCHEMBL1365820 0.93 AR (0.52) ARPGRS1PR3NR3C1ALDH1A1
SCHEMBL1364632 0.93 AR (0.52) ARPGRS1PR3NR3C1ALDH1A1
SCHEMBL1363641 0.92 AR (0.42) ARPGRS1PR3SMN1; SMN2S1PR1
SCHEMBL30054112 0.92 AR (0.42) ARPGRS1PR3POLBL3MBTL1
SCHEMBL1363401 0.92 AR (0.42) ARPGRS1PR3SMN1; SMN2S1PR1
SCHEMBL1365367 0.92 AR (0.42) ARPGRS1PR3POLBL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2260028-B1 SELECTIVE ANDROGEN RECEPTOR MODULATORS RADIUS HEALTH INC (US) 2014-05-07 EP disclosed
US-8629167-B2 Selective androgen receptor modulators RADIUS HEALTH, INC. (US) 2014-01-14 US disclosed
US-8629167-B2 Selective androgen receptor modulators RADIUS HEALTH, INC. (US) 2014-01-14 US disclosed
US-8455525-B2 Selective androgen receptor modulators RADIUS HEALTH, INC. (US) 2013-06-04 US disclosed
US-8455525-B2 Selective androgen receptor modulators RADIUS HEALTH, INC. (US) 2013-06-04 US disclosed
US-20130116288-A1 Selective Androgen Receptor Modulators RADIUS HEALTH, INC. (US) 2013-05-09 US disclosed
US-20130116288-A1 Selective Androgen Receptor Modulators RADIUS HEALTH, INC. (US) 2013-05-09 US disclosed
US-8268872-B2 Selective androgen receptor modulators RADIUS HEALTH, INC. (US) 2012-09-18 US disclosed
US-8268872-B2 Selective androgen receptor modulators RADIUS HEALTH, INC. (US) 2012-09-18 US disclosed
US-8067448-B2 Selective androgen receptor modulators RADIUS HEALTH, INC. (US) 2011-11-29 US disclosed
US-8067448-B2 Selective androgen receptor modulators RADIUS HEALTH, INC. (US) 2011-11-29 US disclosed
US-20110224267-A1 Selective androgen receptor modulators Radius Health,Inc. (US) 2011-09-15 US disclosed
US-20110224267-A1 Selective androgen receptor modulators Radius Health,Inc. (US) 2011-09-15 US disclosed
US-20100041721-A1 SELECTIVE ANDROGEN RECEPTOR MODULATORS RADIUS HEALTH, INC. (US) 2010-02-18 US disclosed
US-20100041721-A1 SELECTIVE ANDROGEN RECEPTOR MODULATORS RADIUS HEALTH, INC. (US) 2010-02-18 US disclosed
US-20090253758-A1 Selective androgen receptor modulators ELLIPSES PHARMA LTD (GB) 2009-10-08 US disclosed
US-20090253758-A1 Selective androgen receptor modulators ELLIPSES PHARMA LTD (GB) 2009-10-08 US disclosed
WO-2009105214-A2 SELECTIVE ANDROGEN RECEPTOR MODULATORS RADIUS HEALTH, INC. (US) 2009-08-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100041721-A1 SELECTIVE ANDROGEN RECEPTOR MODULATORS AR, SHBG, IGF1R AR 1/4885PGR 16/4885S1PR3 3207/4885
US-20110224267-A1 Selective androgen receptor modulators AR, SHBG, GPR119 AR 1/4885PGR 28/4885S1PR3 2534/4885
US-20130116288-A1 Selective Androgen Receptor Modulators AR, SHBG, IGF1R AR 1/4885PGR 17/4885S1PR3 3431/4885
US-20090253758-A1 Selective androgen receptor modulators AR, SHBG, GPR119 AR 1/4885PGR 28/4885S1PR3 2534/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.